Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC.

Ryan SL, Beard S, Barr MP, Umezawa K, Heavey S, Godwin P, Gray SG, Cormican D, Finn SP, Gately KA, Davies AM, Thompson EW, Richard DJ, O'Byrne KJ, Adams MN, Baird AM.

Lung Cancer. 2019 Sep;135:217-227. doi: 10.1016/j.lungcan.2019.07.006. Epub 2019 Jul 12.

PMID:
31446998
2.

Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells.

Gaule P, Mukherjee N, Corkery B, Eustace AJ, Gately K, Roche S, O'Connor R, O'Byrne KJ, Walsh N, Duffy MJ, Crown J, O'Donovan N.

Cancers (Basel). 2019 Apr 17;11(4). pii: E548. doi: 10.3390/cancers11040548.

3.

Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines.

Heavey S, Dowling P, Moore G, Barr MP, Kelly N, Maher SG, Cuffe S, Finn SP, O'Byrne KJ, Gately K.

Sci Rep. 2018 Jan 26;8(1):1652. doi: 10.1038/s41598-018-19688-1.

4.

Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project.

Kerr KM, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Finn S, Biernat W, Vliegen L, Losa JH, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Monkhorst K, Jantus Lewintre E, Tischler V, Clark C, Bertran-Alamillo J, Meldgaard P, Gately K, Wrona A, Vandenberghe P, Felip E, De Luca G, Savic S, Muley T, Smit EF, Dingemans AC, Priest L, Baas P, Camps C, Weder W, Polydoropoulou V, Geiger TR, Kammler R, Sumiyoshi T, Molina MA, Shames DS, Stahel RA, Peters S; ETOP Lungscape Consortium.

Ann Oncol. 2018 Jan 1;29(1):200-208. doi: 10.1093/annonc/mdx629.

PMID:
29186353
5.

IHC-based subcellular quantification provides new insights into prognostic relevance of FLIP and procaspase-8 in non-small-cell lung cancer.

Hutchinson RA, Coleman HG, Gately K, Young V, Nicholson S, Cummins R, Kay E, Hynes SO, Dunne PD, Senevirathne S, Hamilton PW, McArt DG, Longley DB.

Cell Death Discov. 2017 Aug 14;3:17050. doi: 10.1038/cddiscovery.2017.50. eCollection 2017.

6.

Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.

Collins DM, Gately K, Hughes C, Edwards C, Davies A, Madden SF, O'Byrne KJ, O'Donovan N, Crown J.

Cell Immunol. 2017 Sep;319:35-42. doi: 10.1016/j.cellimm.2017.07.005. Epub 2017 Jul 15.

PMID:
28735814
7.

Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Non-Small Cell Lung Cancer.

Adams MN, Burgess JT, He Y, Gately K, Snell C, Zhang SD, Hooper JD, Richard DJ, O'Byrne KJ.

J Thorac Oncol. 2017 Jul;12(7):1071-1084. doi: 10.1016/j.jtho.2017.04.018. Epub 2017 May 6.

8.

Activation and cleavage of SASH1 by caspase-3 mediates an apoptotic response.

Burgess JT, Bolderson E, Adams MN, Baird AM, Zhang SD, Gately KA, Umezawa K, O'Byrne KJ, Richard DJ.

Cell Death Dis. 2016 Nov 10;7(11):e2469. doi: 10.1038/cddis.2016.364.

9.

In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC.

Heavey S, Cuffe S, Finn S, Young V, Ryan R, Nicholson S, Leonard N, McVeigh N, Barr M, O'Byrne K, Gately K.

Oncotarget. 2016 Nov 29;7(48):79526-79543. doi: 10.18632/oncotarget.12755.

10.

Anti-cancer effects of baicalein in non-small cell lung cancer in-vitro and in-vivo.

Cathcart MC, Useckaite Z, Drakeford C, Semik V, Lysaght J, Gately K, O'Byrne KJ, Pidgeon GP.

BMC Cancer. 2016 Sep 1;16:707. doi: 10.1186/s12885-016-2740-0.

11.

Targeting the fibroblast growth factor receptor family in cancer.

Hallinan N, Finn S, Cuffe S, Rafee S, O'Byrne K, Gately K.

Cancer Treat Rev. 2016 May;46:51-62. doi: 10.1016/j.ctrv.2016.03.015. Epub 2016 Apr 12. Review.

PMID:
27109926
12.

Mutational analysis of the insulin-like growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients.

Gately K, Forde L, Gray S, Morris D, Corvin A, Tewari P, O'Byrne K.

Mol Clin Oncol. 2015 Sep;3(5):1073-1079. Epub 2015 Jun 11.

13.

Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer.

O'Callaghan DS, Rexhepaj E, Gately K, Coate L, Delaney D, O'Donnell DM, Kay E, O'Connell F, Gallagher WM, O'Byrne KJ.

Eur Respir J. 2015 Dec;46(6):1762-72. doi: 10.1183/13993003.00176-2014. Epub 2015 Nov 5.

14.

Thymidine Phosphorylase in Cancer; Enemy or Friend?

Elamin YY, Rafee S, Osman N, O Byrne KJ, Gately K.

Cancer Microenviron. 2016 Apr;9(1):33-43. doi: 10.1007/s12307-015-0173-y. Epub 2015 Aug 23. Review.

15.

Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer.

Barr MP, Gray SG, Gately K, Hams E, Fallon PG, Davies AM, Richard DJ, Pidgeon GP, O'Byrne KJ.

Mol Cancer. 2015 Feb 20;14:45. doi: 10.1186/s12943-015-0310-8.

16.

Abnormal levels of heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) in tumour tissue and blood samples from patients diagnosed with lung cancer.

Dowling P, Pollard D, Larkin A, Henry M, Meleady P, Gately K, O'Byrne K, Barr MP, Lynch V, Ballot J, Crown J, Moriarty M, O'Brien E, Morgan R, Clynes M.

Mol Biosyst. 2015 Mar;11(3):743-52. doi: 10.1039/c4mb00384e. Epub 2014 Dec 8.

PMID:
25483567
17.

Epidermal growth factor receptor (EGFR) mutation testing, from bench to practice: a single institute experience.

Shikhrakab H, Elamin YY, O'Brien C, Gately K, Finn S, O'Byrne K, Osman N.

Ir Med J. 2014 Jul-Aug;107(7):201-4.

PMID:
25226713
18.

Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC.

Heavey S, Godwin P, Baird AM, Barr MP, Umezawa K, Cuffe S, Finn SP, O'Byrne KJ, Gately K.

Cancer Biol Ther. 2014 Oct;15(10):1367-77. doi: 10.4161/cbt.29841. Epub 2014 Jul 15.

19.

The establishment of an ISO compliant cancer biobank for Jordan and its neighboring countries through knowledge transfer and training.

Barr MP, Souan L, MacGabhann P, Müller J, Al Ashhab M, Jasser M, Hamza K, Al Hassoon S, Kuhn U, Infante D, Lawlor D, Gately K, Amireh E, O'Byrne K, Sughayer MA.

Biopreserv Biobank. 2014 Feb;12(1):3-12. doi: 10.1089/bio.2013.0072.

20.

Prognostic impact of vascular and lymphovascular invasion in early lung cancer.

Al-Alao BS, Gately K, Nicholson S, McGovern E, Young VK, O'Byrne KJ.

Asian Cardiovasc Thorac Ann. 2014 Jan;22(1):55-64. doi: 10.1177/0218492313478431. Epub 2013 Sep 4.

PMID:
24585645
21.

Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer.

Cathcart MC, Gately K, Cummins R, Drakeford C, Kay EW, O'Byrne KJ, Pidgeon GP.

Biochim Biophys Acta. 2014 May;1842(5):747-55. doi: 10.1016/j.bbadis.2014.01.011. Epub 2014 Jan 28.

22.

Building a state coalition for nursing home excellence.

Beck C, Gately KJ, Lubin S, Moody P, Beverly C.

Gerontologist. 2014 Feb;54 Suppl 1:S87-97. doi: 10.1093/geront/gnt110.

23.

Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer.

Riley JS, Hutchinson R, McArt DG, Crawford N, Holohan C, Paul I, Van Schaeybroeck S, Salto-Tellez M, Johnston PG, Fennell DA, Gately K, O'Byrne K, Cummins R, Kay E, Hamilton P, Stasik I, Longley DB.

Cell Death Dis. 2013 Dec 5;4:e951. doi: 10.1038/cddis.2013.481.

24.

High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer.

Gately K, Forde L, Cuffe S, Cummins R, Kay EW, Feuerhake F, O'Byrne KJ.

Clin Lung Cancer. 2014 Jan;15(1):58-66. doi: 10.1016/j.cllc.2013.08.005. Epub 2013 Nov 7.

PMID:
24210543
25.

Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC.

Heavey S, O'Byrne KJ, Gately K.

Cancer Treat Rev. 2014 Apr;40(3):445-56. doi: 10.1016/j.ctrv.2013.08.006. Epub 2013 Aug 26. Review.

PMID:
24055012
26.

Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma.

Rani S, Gately K, Crown J, O'Byrne K, O'Driscoll L.

Cancer Biol Ther. 2013 Dec;14(12):1104-12. doi: 10.4161/cbt.26370. Epub 2013 Sep 4.

27.

Targeting nuclear factor-kappa B to overcome resistance to chemotherapy.

Godwin P, Baird AM, Heavey S, Barr MP, O'Byrne KJ, Gately K.

Front Oncol. 2013 May 16;3:120. doi: 10.3389/fonc.2013.00120. eCollection 2013.

28.

RanGTPase: a candidate for Myc-mediated cancer progression.

Yuen HF, Gunasekharan VK, Chan KK, Zhang SD, Platt-Higgins A, Gately K, O'Byrne K, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.

J Natl Cancer Inst. 2013 Apr 3;105(7):475-88. doi: 10.1093/jnci/djt028. Epub 2013 Mar 6.

PMID:
23468463
29.

Surgical resection for non-small cell lung cancer: clinical features and outcomes for a consecutive series at an Irish tertiary referral centre.

Al-Alao BS, O'Callaghan DS, Gately K, Nicholson S, Coate LE, O'Connell F, McGovern E, O'Byrne KJ, Young VK.

Ir J Med Sci. 2013 Jun;182(2):217-25. doi: 10.1007/s11845-012-0863-0. Epub 2012 Nov 9.

PMID:
23139062
30.

The locus for an inherited cataract in sheep maps to ovine chromosome 6.

Wilson GR, Morton JD, Palmer DN, McEwan JC, Gately K, Anderson RM, Dodds KG.

Mol Vis. 2012;18:1384-94. Epub 2012 May 31.

31.

The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.

Gately K, O'Flaherty J, Cappuzzo F, Pirker R, Kerr K, O'Byrne K.

J Clin Pathol. 2012 Jan;65(1):1-7. doi: 10.1136/jclinpath-2011-200275. Epub 2011 Oct 29. Review.

PMID:
22039281
32.

Design, construction, and analysis of cell line arrays and tissue microarrays for gene expression analysis.

Gately K, Kerr K, O'Byrne K.

Methods Mol Biol. 2011;784:139-53. doi: 10.1007/978-1-61779-289-2_10.

PMID:
21898218
33.

Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study.

Gately K, Al-Alao B, T Dhillon, Mauri F, Cuffe S, Seckl M, O'Byrne K.

Lung Cancer. 2012 Feb;75(2):217-22. doi: 10.1016/j.lungcan.2011.06.012. Epub 2011 Jul 30.

PMID:
21802763
34.

PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.

Paul I, Savage KI, Blayney JK, Lamers E, Gately K, Kerr K, Sheaff M, Arthur K, Richard DJ, Hamilton PW, James JA, O'Byrne KJ, Harkin DP, Quinn JE, Fennell DA.

J Pathol. 2011 Aug;224(4):564-74. doi: 10.1002/path.2925. Epub 2011 Jun 27.

PMID:
21706479
35.

Prostacyclin synthase expression and epigenetic regulation in nonsmall cell lung cancer.

Cathcart MC, Gray SG, Baird AM, Boyle E, Gately K, Kay E, Cummins R, Pidgeon GP, O'Byrne KJ.

Cancer. 2011 Nov 15;117(22):5121-32. doi: 10.1002/cncr.26168. Epub 2011 Apr 26.

36.

Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer.

Cathcart MC, Gately K, Cummins R, Kay E, O'Byrne KJ, Pidgeon GP.

Mol Cancer. 2011 Mar 9;10:25. doi: 10.1186/1476-4598-10-25.

37.

A role for IGF-1R-targeted therapies in small-cell lung cancer?

Gately K, Collins I, Forde L, Al-Alao B, Young V, Gerg M, Feuerhake F, O'Byrne K.

Clin Lung Cancer. 2011 Jan;12(1):38-42. doi: 10.3816/CLC.2011.n.005.

PMID:
21273178
38.

Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing.

Wilson TR, Redmond KM, McLaughlin KM, Crawford N, Gately K, O'Byrne K, Le-Clorrenec C, Holohan C, Fennell DA, Johnston PG, Longley DB.

Cell Death Differ. 2009 Oct;16(10):1352-61. doi: 10.1038/cdd.2009.76. Epub 2009 Jun 19.

39.

Transcriptional regulation of IRS5/DOK4 expression in non-small-cell lung cancer cells.

Gray SG, Al-Sarraf N, Baird AM, Gately K, McGovern E, O'Byrne KJ.

Clin Lung Cancer. 2008 Nov;9(6):367-74. doi: 10.3816/CLC.2008.n.053.

PMID:
19073520
40.

Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases.

Al-Sarraf N, Gately K, Lucey J, Aziz R, Doddakula K, Wilson L, McGovern E, Young V.

Eur J Cardiothorac Surg. 2008 Oct;34(4):892-7. doi: 10.1016/j.ejcts.2008.07.023. Epub 2008 Aug 21. Review.

PMID:
18722132
41.

Synthesis, biological evaluation and molecular modelling of N-heterocyclic dipeptide aldehydes as selective calpain inhibitors.

Jones MA, Morton JD, Coxon JM, McNabb SB, Lee HY, Aitken SG, Mehrtens JM, Robertson LJ, Neffe AT, Miyamoto S, Bickerstaffe R, Gately K, Wood JM, Abell AD.

Bioorg Med Chem. 2008 Jul 15;16(14):6911-23. doi: 10.1016/j.bmc.2008.05.048. Epub 2008 May 27.

PMID:
18571418
42.

Mediastinal lymph node staging by means of positron emission tomography is less sensitive in elderly patients with non-small-cell lung cancer.

Al-Sarraf N, Gately K, Lucey J, Wilson L, McGovern E, Young V.

Clin Lung Cancer. 2008 Jan;9(1):39-43. doi: 10.3816/CLC.2008.n.007.

PMID:
18282357
43.

Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography.

Al-Sarraf N, Aziz R, Gately K, Lucey J, Wilson L, McGovern E, Young V.

Eur J Cardiothorac Surg. 2008 Jan;33(1):104-9. Epub 2007 Oct 30.

PMID:
17977738
44.

Lymph node staging by means of positron emission tomography is less accurate in non-small cell lung cancer patients with enlarged lymph nodes: analysis of 1,145 lymph nodes.

Al-Sarraf N, Gately K, Lucey J, Wilson L, McGovern E, Young V.

Lung Cancer. 2008 Apr;60(1):62-8. Epub 2007 Oct 24.

PMID:
17920724
45.

Factors causing inaccurate staging of mediastinal nodal involvement in non-small cell lung cancer patients staged by positron emission tomography.

Al-Sarraf N, Aziz R, Doddakula K, Gately K, Wilson L, McGovern E, Young V.

Interact Cardiovasc Thorac Surg. 2007 Jun;6(3):350-3. Epub 2007 Mar 29.

PMID:
17669863
46.

Predictors of acute renal failure requiring renal replacement therapy post cardiac surgery in patients with preoperatively normal renal function.

Doddakula K, Al-Sarraf N, Gately K, Hughes A, Tolan M, Young V, McGovern E.

Interact Cardiovasc Thorac Surg. 2007 Jun;6(3):314-8. Epub 2007 Mar 7.

PMID:
17669854
47.

Tumor necrosis factor-alpha and interleukin-10 gene expression in peripheral blood mononuclear cells after cardiac surgery.

Duggan E, Caraher E, Gately K, O'Dwyer M, McGovern E, Kelleher D, McManus R, Ryan T.

Crit Care Med. 2006 Aug;34(8):2134-9.

PMID:
16763510
48.

Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML.

McCann SR, Gately K, Conneally E, Lawler M.

Blood. 2003 Feb 1;101(3):1200-1. No abstract available. Erratum in: Blood. 2003 Mar 1;101(5):1683.

PMID:
12529295

Supplemental Content

Loading ...
Support Center